/
MYO
$1.11+$0.08 (+7.77%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$39.8M
39M shares
52-week range
$0.61 – $2.38
28% from low
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Exchange
XASE
CS
Borrow rate
6.67%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-9.29
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $3.8M | $7.6M | $13.9M | $15.6M | $19.2M | $32.6M | $40.9M |
| Cost of revenue | $728.3K | $917.6K | $2.6M | $3.5M | $5.3M | $6.1M | $9.4M | $14.0M |
| Gross profit | $1.7M | $2.9M | $5.0M | $10.3M | $10.3M | $13.2M | $23.2M | $26.9M |
| Gross margin | 70.2% | 76.1% | 65.7% | 74.4% | 65.9% | 68.5% | 71.2% | 65.7% |
| R&D | $1.8M | $2.2M | $1.7M | $2.6M | $2.5M | $2.6M | $4.8M | $6.9M |
| Operating income | −$10.5M | −$10.8M | −$10.5M | −$10.3M | −$10.7M | −$8.2M | −$6.2M | −$14.4M |
| EBITDA | −$10.5M | −$10.7M | −$11.0M | −$9.9M | −$10.1M | −$7.5M | −$5.0M | −$12.4M |
| Net income | −$10.3M | −$10.7M | −$11.6M | −$10.4M | −$10.7M | −$8.1M | −$6.2M | −$15.6M |
| Net margin | -422.1% | -279.1% | -152.5% | -74.9% | -68.9% | -42.3% | -19.0% | -38.1% |
| EPS (diluted) | -25.15 | -19.20 | -3.62 | -1.78 | -1.52 | -0.28 | -0.16 | -0.37 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $44M | $-0.31 | $-0.36–$-0.25 | 3 |
| 2027 | $50M | $-0.24 | $-0.30–$-0.18 | 3 |
| 2028 | $67M | $-0.05 | $-0.05–$-0.05 | 1 |
| 2029 | $82M | $0.22 | $0.20–$0.24 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
www.myomo.com- Employees
- 195
- IPO / List date
- Jun 12, 2017
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds MYO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 23,600 | $15.9K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2020-01-31 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded MYO yet.
